Literature DB >> 12834365

Acute exacerbations in chronic obstructive pulmonary disease: current strategies with pharmacological therapy.

Charles S Hall1, Andreas Kyprianou, Alan M Fein.   

Abstract

In acute exacerbation of chronic obstructive pulmonary disease (AECOPD), short-acting inhaled bronchodilators, such as salbutamol (albuterol) and ipratropium bromide, have proven useful. In patients who are refractory to these agents, intravenous aminophylline should be considered. Corticosteroids should also be used, either in the outpatient or inpatient setting. The duration of corticosteroids should probably not exceed 2 weeks and the optimum dosage is yet to be determined. Antibacterials, especially in patients with purulent or increased sputum, should be used, guided by the local antibiogram of the key microbes. Controlled oxygen therapy improves outcome in hypoxaemic patients and arterial blood gases should be performed to ensure hypercarbia is not becoming excessive. Should patients be in distress despite the above measures or if there is acidaemia or hypercarbia, noninvasive positive pressure ventilation could be used to improve outcomes without resorting to invasive mechanical ventilation. Mucous-clearing drugs and chest physiotherapy have no proven beneficial role in AECOPD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12834365     DOI: 10.2165/00003495-200363140-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  38 in total

1.  Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial.

Authors:  L Davies; R M Angus; P M Calverley
Journal:  Lancet       Date:  1999-08-07       Impact factor: 79.321

Review 2.  Long acting beta(2) agonists and theophylline in stable chronic obstructive pulmonary disease.

Authors:  M Cazzola; C F Donner; M G Matera
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

3.  Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease.

Authors:  T A Seemungal; G C Donaldson; A Bhowmik; D J Jeffries; J A Wedzicha
Journal:  Am J Respir Crit Care Med       Date:  2000-05       Impact factor: 21.405

4.  Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD.

Authors:  S G Adams; J Melo; M Luther; A Anzueto
Journal:  Chest       Date:  2000-05       Impact factor: 9.410

Review 5.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

6.  Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD.

Authors:  M Miravitlles; C Espinosa; E Fernández-Laso; J A Martos; J A Maldonado; M Gallego
Journal:  Chest       Date:  1999-07       Impact factor: 9.410

Review 7.  Role of antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease.

Authors:  R L Russo; M D'Aprile
Journal:  Ann Pharmacother       Date:  2001-05       Impact factor: 3.154

8.  Effects of combined treatment with glycopyrrolate and albuterol in acute exacerbation of chronic obstructive pulmonary disease.

Authors:  R K Cydulka; C L Emerman
Journal:  Ann Emerg Med       Date:  1995-04       Impact factor: 5.721

9.  Corticosteroids contribute to muscle weakness in chronic airflow obstruction.

Authors:  M Decramer; L M Lacquet; R Fagard; P Rogiers
Journal:  Am J Respir Crit Care Med       Date:  1994-07       Impact factor: 21.405

10.  Decreased duration of emergency department treatment of chronic obstructive pulmonary disease exacerbations with the addition of ipratropium bromide to beta-agonist therapy.

Authors:  M Shrestha; T O'Brien; R Haddox; H S Gourlay; G Reed
Journal:  Ann Emerg Med       Date:  1991-11       Impact factor: 5.721

View more
  2 in total

1.  Compound Ipratropium Bromide plus Budesonide Inhalation in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Its Effect on Heparin-Binding Protein.

Authors:  Yuan Dong; Qingling Li
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-04       Impact factor: 2.650

2.  [Acute exacerbation of COPD].

Authors:  C G Lange; B Scheuerer; P Zabel
Journal:  Internist (Berl)       Date:  2004-05       Impact factor: 0.743

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.